Deloitte has been hit hardest by the Trump administration's cost-cutting initiative under the Department of Government ...

Projected return on investment in pharma research and development (R&D) in 2024 has risen to 5.9%, continuing the upward ...

DOGE has either terminated or modified 127 federal contracts with Deloitte, leading to an estimated $371.8 million in ...

Deloitte has borne the brunt of the Department of Government Efficiency's crackdown, losing 124 federal contracts since ...

A recent report highlights significant contract changes under the Department of Government Efficiency (DOGE) initiative, led ...

Deloitte, in a series of annual reports on "Measuring the return from pharmaceutical innovation," in collaboration with other member firms, has provided insights into the state of biopharma R&D ...

Deloitte is making strides to become a key player in the space industry for government and commercial services.

The centre will power next-gen capabilities such as 5G, 6G, IoT, industrial metaverse, space tech, physical robotics, and ...

Deloitte's AI Forum 2025 in India highlighted how Global Capability Centers (GCCs) are increasingly adopting AI across ...